EP4419886A1 - A composition, method and kit for extracting a narcotic compound from a biological sample - Google Patents
A composition, method and kit for extracting a narcotic compound from a biological sampleInfo
- Publication number
- EP4419886A1 EP4419886A1 EP21961285.0A EP21961285A EP4419886A1 EP 4419886 A1 EP4419886 A1 EP 4419886A1 EP 21961285 A EP21961285 A EP 21961285A EP 4419886 A1 EP4419886 A1 EP 4419886A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- composition
- sample
- liquid mixture
- weight
- tube
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4055—Concentrating samples by solubility techniques
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/02—Solvent extraction of solids
- B01D11/0288—Applications, solvents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D11/00—Solvent extraction
- B01D11/04—Solvent extraction of solutions which are liquid
- B01D11/0492—Applications, solvents used
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4055—Concentrating samples by solubility techniques
- G01N2001/4061—Solvent extraction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
Definitions
- This invention relates to extraction of narcotic compounds from a sample, in particular this invention relates to a novel composition, method and kit including the novel composition for extracting narcotic compounds from a biological sample. background
- LLE liquid/liquid extractions
- a composition for extraction of narcotic compounds from a sample including a first liquid mixture and second solid composition: - the first liquid mixture having, a source of heptane, either n-heptane or heptane having mixed isomers and/or enantiomers thereof comprising from about 10% to about 25%, by weight of the liquid mixture, an organochloride compound being dichloromethane comprising from about 25% to about 35%, by weight of the liquid mixture, a chlorinated hydrocarbon being 1 ,2-Dichloroethane comprising from about 30% to about 45%, by weight of the liquid mixture, a source of liquid propane comprising from about 5% to about 21 %, by weight of the liquid mixture, the second solid composition; having a source of sodium chloride, comprising from about 16% to about 63 %, by weight of the second solid composition, a source of sodium carbonate, comprising from about 17 % to about 34 %, by weight of the second solid composition, a
- the final composition may have a pH of 9.
- the source of heptane may have a volume of between 1 and 1 .4 micro litre.
- the dichloro methane solvent may have a volume of between 0.7 and 2 micro litre.
- the dichloro ethane solvent may have a volume of between 0.7 and 4 micro litre.
- the liquid propane may have a volume of between 0.5 and 4 micro litre.
- the sodium chloride may have a mass of between 0.5 and 1 grams. In one formulation the sodium carbonate may have a mass of between 0.15 and 1 grams.
- the sodium bi carbonate may have a mass of between 0.15 and 1 grams.
- the sodium chloride, sodium carbonate and sodium bi-carbonate may be in the form of a powder.
- the sample may be in the form of any one or more of the group including a biological sample, a petroleum sample, an ink sample, a dye sample, an organic sample or the like.
- the biological sample may be selected from the group including blood, urine, tissue, stomach contents or the like.
- a kit for extraction of narcotic compounds from a sample including: - a composition having a first liquid mixture and second solid composition as hereinbefore described; and a tube which is configured to contain the composition therein and further be configured to receive a sample for extraction of narcotic compounds from the sample.
- the sample may be in the form of any one or more of the group including a biological sample, a petroleum sample, an ink sample, a dye sample, an organic sample or the like.
- the tube may be a pathology tube.
- the biological sample may be selected from the group including blood, urine, tissue, stomach contents or the like.
- a method for extraction of narcotic compounds from a sample including the following steps: providing a tube having a composition therein, said composition having a first liquid mixture and second solid composition as hereinbefore described; and adding a desired biological sample to the tube.
- the sample may be a 5ml urine sample.
- An additional step may include vortexing the tube for at least 2 minutes.
- Yet another step may include centrifuging the tube for at least 3 minutes at a speed of at least 4000 rpm.
- a still further step may include additional centrifuging of the tube for another 3 minutes at a speed of at least 4000 rpm.
- a still further step may include transferring the upper layer of the fluid inside the tube and evaporating said upper layer at 40 degrees Celsius under nitrogen.
- a further step may include re-constitution of the residue using 50 micro litres of ethyl acetate.
- a further step may include extracting 2 micro litres of extract and injecting said extract into the confirmatory instrument.
- the confirmatory instrument may be a gas chromatography and mass spectrometry (GC-MS).
- Figure 1 is a perspective view of a kit for extraction of narcotic compounds from a sample, in accordance with a second aspect of the invention, including a composition having a first liquid mixture and second solid composition as described in accordance with a first aspect of the invention;
- Figure 2 is another perspective view of a kit as shown in Figure 1 , wherein the first liquid mixture and second solid composition has been mixed to form a final composition;
- Figure 3 is another perspective view of a kit as shown in Figure 2, wherein, is use, a sample is added to the final composition;
- Figure 4 is a schematic showing a flow diagram of a method in accordance with a third aspect of the invention.
- a composition for extraction of narcotic compounds from a sample including a first liquid mixture and second solid composition, the first liquid mixture having, a source of heptane, either n-heptane or heptane having mixed isomers and/or enantiomers thereof comprising from about 10% to about 25%, by weight of the liquid mixture, an organochloride compound being dichloromethane comprising from about 25% to about 35%, by weight of the liquid mixture, a chlorinated hydrocarbon being 1 ,2- Dichloroethane comprising from about 30% to about 45%, by weight of the liquid mixture, a source of liquid propane comprising from about 5% to about 21 %, by weight of the liquid mixture, the second solid composition, having a source of sodium chloride, comprising from about 16% to about 63 %, by weight of the second solid composition, a source of sodium carbonate, comprising from about 17 % to about 34 %, by weight of the second solid composition,
- the final composition has a pH of 9.
- the source of heptane has a volume of between 1 and 1 .4 micro litre.
- the dichloro methane solvent has a volume of between 0.7 and 2 micro litre.
- the dichloro ethane solvent has a volume of between 0.7 and 4 micro litre.
- the liquid propane has a volume of between 0.5 and 4 micro litre.
- the sodium chloride has a mass of between 0.5 and 1 grams.
- the sodium carbonate has a mass of between 0.15 and 1 grams.
- the sodium bi carbonate has a mass of between 0.15 and 1 grams.
- the sodium chloride, sodium carbonate and sodium bi-carbonate is in the form of a powder.
- the biological sample is selected from the group including blood, urine, tissue, stomach contents or the like.
- kits 100 for extraction of narcotic compounds from a sample including a composition 1 10 having a first liquid mixture 114 and second solid composition 1 16 as hereinbefore described, and a tube 1 18 which is configured to contain the composition 1 10 therein and further be configured to receive a sample 1 12 for extraction of narcotic compounds from the sample 1 12.
- the sample 1 12 is in the form of any one or more of the group including a biological sample, a petroleum sample, an ink sample, a dye sample, an organic sample or the like.
- the biological sample 1 12 is selected from the group including blood, urine, tissue, stomach contents or the like.
- a method 200 for extraction of narcotic compounds from a sample including the following steps, providing a tube 218 having a composition 210 therein, said composition 210 having a first liquid mixture 214 and second solid composition 216 as hereinbefore described, and adding a desired biological sample 212 to the tube 218.
- the desired biological sample 212 is a 5ml urine sample.
- Yet another step 202 includes centrifuging the tube 218 for at least 3 minutes at a speed of at least 4000 rpm.
- a still further step 203 includes additional centrifuging of the tube 218 for another 3 minutes at a speed of at least 4000 rpm.
- a still further step 204 includes transferring the upper layer of the fluid inside the tube 218 and evaporating said upper layer at 40 degrees Celsius under nitrogen.
- a further step 205 includes re-constitution of the residue using 50 micro litres of ethyl acetate.
- a further step 206 includes extracting 2 micro litres of extract and injecting said extract into the confirmatory instrument 220.
- the confirmatory instrument 220 is a gas chromatography and mass spectrometry (GC-MS).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2021/059595 WO2023067370A1 (en) | 2021-10-19 | 2021-10-19 | A composition, method and kit for extracting a narcotic compound from a biological sample |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4419886A1 true EP4419886A1 (en) | 2024-08-28 |
| EP4419886A4 EP4419886A4 (en) | 2025-10-15 |
Family
ID=86058837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP21961285.0A Pending EP4419886A4 (en) | 2021-10-19 | 2021-10-19 | Composition, method and kit for extracting a narcotic compound from a biological sample |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP4419886A4 (en) |
| WO (1) | WO2023067370A1 (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2687854A1 (en) * | 2012-07-19 | 2014-01-22 | Chiron AS | Test kit for the quantitative determination of narcotic drugs |
| US9726684B1 (en) * | 2015-01-18 | 2017-08-08 | Hound Labs, Inc. | Compositions for target substance detection and measurement |
| US9823259B1 (en) * | 2016-04-08 | 2017-11-21 | Walter Nichols | Detection device for cannabinoid use |
| CN111868530B (en) * | 2018-02-14 | 2024-06-11 | 萨琳格纳斯提克斯有限公司 | Methods and devices for detecting analytes |
| KR102188845B1 (en) * | 2018-10-08 | 2020-12-09 | 한국과학기술원 | Colorimetric drug sensors with drug detecting color change dye anchored one dimensional nanofiber membrane and manufacturing method thereof |
-
2021
- 2021-10-19 EP EP21961285.0A patent/EP4419886A4/en active Pending
- 2021-10-19 WO PCT/IB2021/059595 patent/WO2023067370A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023067370A1 (en) | 2023-04-27 |
| EP4419886A4 (en) | 2025-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dmitrienko et al. | Homogeneous liquid–liquid microextraction of organic compounds | |
| Berthod et al. | Countercurrent chromatography: People and applications | |
| Rajabi et al. | Ionic liquid-based ultrasound-assisted surfactant-emulsified microextraction for simultaneous determination of three important flavoring compounds in plant extracts and urine samples | |
| CN101801911A (en) | assay methods for memantine | |
| JP2011513710A (en) | Methods and kits for determining the presence and amount of vitamin D analogs in a sample | |
| Santurio et al. | Determination of glibenclamide in human plasma by solid-phase extraction and high-performance liquid chromatography | |
| EP4419886A1 (en) | A composition, method and kit for extracting a narcotic compound from a biological sample | |
| Craig | Extraction | |
| Tang et al. | Extraction and quantitative analysis of tropane alkaloids in Radix physochlainae by emulsion liquid membrane with tropine-based ionic liquid | |
| Seger et al. | Apolar chromatography on Sephadex LH-20 combined with high-speed counter-current chromatography: High yield strategy for structurally closely related analytes—Destruxin derivatives from Metarhizium anisopliae as a case study | |
| Lurie et al. | The determination of anabolic steroids by MECC, gradient HPLC, and capillary GC | |
| CN113278608B (en) | Chloroform substitute reagent for nucleic acid extraction and separation | |
| Vincenti et al. | Unearthed opium: development of a UHPLC-MS/MS method for the determination of Papaver somniferum alkaloids in Daunian vessels | |
| Schafhauser et al. | Isolation and purification of natural products from microbial cultures | |
| Takatsuki | Gas chromatographic/mass spectrometric determination of oxolinic, nalidixic, and piromidic acid in fish | |
| Joe Jr et al. | High performance liquid chromatography with fluorescence and ultraviolet detection of polynuclear aromatic hydrocarbons in barley malt | |
| US20140224735A1 (en) | Liquid-Liquid Extraction Process And Apparatus | |
| Madej et al. | Drug screening in human plasma by cloud-point extraction and HPLC | |
| Craft et al. | Preparation and certification of standard reference material 1507: 11-nor-. DELTA. 9-tetrahydrocannabinol-9-carboxylic acid in freeze-dried urine | |
| Lawrence et al. | Supercritical fluid extraction of benzodiazepines in solid dosage forms | |
| Elkhouly et al. | Investigation of the Unsaponifiable and Saponifiable Matters of Higginsia sp. sponge by GC/MS | |
| Yedamenko et al. | Application of surfactant micellar solutions as extractants and mobile phases for TLC-determination of purine bases and doping agents in biological liquids | |
| About-Khalil et al. | High-performance liquid chromatographic determination of chloramphenicol and four analogues using reductive and oxidative electrochemical and ultraviolet detection | |
| RU2806370C1 (en) | Method of simultaneous quantitative determination of persistent organochlorine pesticides in animal hair using gas chromatography-mass spectrometry | |
| Sadjadi et al. | Analysis of immunosuppressants from whole blood using protein precipitation and LC/MS/MS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20240328 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: G01N0001400000 Ipc: B01D0011020000 |